Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5276079
Max Phase: Preclinical
Molecular Formula: C23H15F3N2O
Molecular Weight: 392.38
Associated Items:
ID: ALA5276079
Max Phase: Preclinical
Molecular Formula: C23H15F3N2O
Molecular Weight: 392.38
Associated Items:
Canonical SMILES: O=c1c2ccccc2nc(-c2ccccc2)n1/C=C/c1cccc(C(F)(F)F)c1
Standard InChI: InChI=1S/C23H15F3N2O/c24-23(25,26)18-10-6-7-16(15-18)13-14-28-21(17-8-2-1-3-9-17)27-20-12-5-4-11-19(20)22(28)29/h1-15H/b14-13+
Standard InChI Key: PIBFFBRIXAQDTH-BUHFOSPRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 392.38 | Molecular Weight (Monoisotopic): 392.1136 | AlogP: 5.71 | #Rotatable Bonds: 3 |
Polar Surface Area: 34.89 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 3.75 | CX LogP: 5.84 | CX LogD: 5.84 |
Aromatic Rings: 4 | Heavy Atoms: 29 | QED Weighted: 0.45 | Np Likeness Score: -0.79 |
1. Alagarsamy V, Chitra K, Saravanan G, Solomon VR, Sulthana MT, Narendhar B.. (2018) An overview of quinazolines: Pharmacological significance and recent developments., 151 [PMID:29656203] [10.1016/j.ejmech.2018.03.076] |
Source(1):